期刊文献+

表浅性膀胱癌第二次经尿道切除80例临床分析

下载PDF
导出
摘要 目的:探讨表浅性膀胱癌(Ta和T1)进行第二次经尿道膀胱肿瘤切除(TURBt)的临床意义。方法:回顾分析我院2004~2008年初次TURBt诊断为表浅性膀胱癌的80例患者接受2次TURBt,均为初发,2次TURBt在第一次手术后4~6周常规进行,了解是否存在残余肿瘤、肿瘤位置、病理分级、分期。结果:38例(47.5%)发现有残余肿瘤,其中原来位置30例(78.9%),其他位置8例(21.1%);肿瘤分期:未见肿瘤42例(52.5%),Ta5例(6.25%),T117例(21.25%),Tis8例(10%),T2期以上8例(10%);病理分期升级(T1以上或同时有Tis)占20%。根据2次TURBt结果,有16例(20%)行根治性全膀胱切除术。结论:表浅性膀胱癌应该常规进行第二次TURBt,能更彻底切除肿瘤,更早期判断患者应该接受根治性全膀胱切除术。
出处 《现代医药卫生》 2009年第7期1017-1018,共2页 Journal of Modern Medicine & Health
  • 相关文献

参考文献7

  • 1李磊,李长岭.浅表性膀胱癌的灌注治疗[J].现代泌尿外科杂志,2004,9(4):243-246. 被引量:15
  • 2BedfordW.Invasive bladder cancer-where dowe go from here[J].Urology, 1996,155 : 1910.
  • 3Engelhardt PF,Simak R,Riedl CR,et al.Is a second look TURB in patients with superficial bladder cancer necessary[J]. Eur Urol, 1999, 35 : A93.
  • 4Kriegmair M, Zaak D, Rothenberger KH, et al.Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscpy[J].J Urol, 2002,168:475.
  • 5Zurkirchen MA,Sulser T,GaspertA,et al. Second transurethtal resection of superficial transition',d cell carcinoma of the bladder:a must even for experienced urologists[J].Urol Int. 2004.99.
  • 6吴阶平.吴阶平泌尿外科[M].济南:山东科学技术出版社,2004.973.
  • 7Oosterlinck W, Lobel B, Jakse G, et al.European association of urology(EAU) working group on oncological urology guidelines on bladder cancer[J ].Eur Urol,2002,41 : 105.

二级参考文献24

  • 1[22]Sylvester R, van der Meijiden APM, Oosterlinck W, et al. The side effects of bacillus Calmtte-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficiency. Results from an EORTC Genito-Urinary Group phase Ⅲ trial [J]. Eur Urol Suppl, 2002, 2(1), 191 [Abstract 753].
  • 2[23]Saint F, Kurth N, Maille P, et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy [J]. Int J Cancer, 2003, 107(3): 434-440.
  • 3[24]Pagliaro LC, Keyhani A, Williams D, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy [J]. J Clin Oncol, 2003, 21(12): 2247-2253.
  • 4[1]Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by single intravesical instillation of epirubicin or water in single state Ta, T1 papillary carcinoma of the bladder [J]. J Urol, 1993, 149(4):749-752.
  • 5[2]The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer [J]. Br J Urol, 1994, 73 (6): 632-638.
  • 6[3]Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer [J]. Urol Clin North Am, 1992, 19(3): 573-580.
  • 7[4]Van der Heijden AG, Witjes JA. Intravesical chemotherapy: An update-new trend and perspectives [J]. EAU Update Series, 2003(1): 71-79.
  • 8[5]Kobayashi M, Sugaya Y, Yuzawa M, et al. Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor [J]. Gan To Kagaku Ryoho, 1998, 25(11):1771-1774.
  • 9[6]Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder [J]. J Urol, 1990, 144(3):658-661.
  • 10[7]Torti FM, Shortliffe LD, Williams RD, et al. Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study [J]. J Clin Oncol, 1988, 6(3): 476-483.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部